It functions by binding to CD20 expressed on the surface of target B cells and the CD3ε chain (CD3ε) on effector T cells, thereby inducing T cell activation, proliferation, cytokine release, and tumor cell lysis, providing a new treatment option for R/R DLBCL patients.297–306. This evidence concerns the gene CD3E and diffuse large B-cell lymphoma.